Informations générales (source: ClinicalTrials.gov)
Evaluation of Stroop Effect in Patients With Schizophrenia (STROOP)
Interventional
N/A
University Hospital, Clermont-Ferrand (Voir sur ClinicalTrials)
septembre 2016
juin 2019
29 juin 2024
The main objective of this study is to assess whether attention deficits and executive
functions in patients with schizophrenia are general (semantic and response conflict) or
specific (semantic or response conflict).
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Clermont-Ferrand - 63003 - Clermont-Ferrand - Auvergne - France | Patrick LACARIN | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
For both:
- MMSE score greater than or equal to, 22 if no grade ; 23 if study certificate or CAP
or college without patent ; 25 if patent or school without the tray ; 26 or more
when bin
- IQ ≥ 75 (fNART)
- Lextale score ≥ 28
- Age: between 18 and 45 years
For patients :
- DSM-5 criteria of schizophrenia
- Patients followed as outpatients,
- Age of onset of the disease less than 40 years,
- Patients whose disease has stabilized: no changes psychotropic treatment for at
least 1 month
- Not more of a benzodiazepine,
- Patients on protection of justice or not,
For controls :
- Matched for sex to patient
- Age-matched (+/- 3 years) to patient
- Matched for IQ (score fNART +/- 10% to patients
- Matched for Lextale score+/- 10% to patients
For both:
- MMSE score greater than or equal to, 22 if no grade ; 23 if study certificate or CAP
or college without patent ; 25 if patent or school without the tray ; 26 or more
when bin
- IQ ≥ 75 (fNART)
- Lextale score ≥ 28
- Age: between 18 and 45 years
For patients :
- DSM-5 criteria of schizophrenia
- Patients followed as outpatients,
- Age of onset of the disease less than 40 years,
- Patients whose disease has stabilized: no changes psychotropic treatment for at
least 1 month
- Not more of a benzodiazepine,
- Patients on protection of justice or not,
For controls :
- Matched for sex to patient
- Age-matched (+/- 3 years) to patient
- Matched for IQ (score fNART +/- 10% to patients
- Matched for Lextale score+/- 10% to patients
For patients :
- Any other comorbid psychiatric diagnosis of Axis I DSM-5
- Extrapyramidal syndrome or tardive dyskinesia (AIMS score <2 BARS score <2 and score
Simpson and Angus <3)
- Calgary depression scale ≥ 6
- Current or past addiction to all toxic substances (including alcohol and cannabis)
except tobacco.
- Current or past use of all toxic consumption (excluding alcohol, tobacco and
cannabis).
- Use of alcohol or cannabis before the age of 15 years
- Alcohol abuse in the past 6 months.
- Cannabis abuse in the past 6 months and cannabis use in the last 3 months.
- Patients with impaired vision or hearing preventing the realization of the tests.
For controls:
- Any psychiatric diagnosis according to DSM-5, including addictions (excluding
tobacco)
- Score HADS Anxiety ≥ 8 and Depression ≥ 8
- SCL90R: global severity score GSI> 0.33 for women and> 0.27 for men, or score
diversity PST symptoms> 18.49 for men and> 21.97 for women or score of degree of
discomfort PSDI> 1.27 for men and> 1.3 for women, scoring in the subscale Psychotic
Features> 0.
- Presence of a personality disorder at PDQ4 +
- Head injuries, brain injuries or diseases,
- vision or hearing problems preventing the realization of the tests.
- Current or past addiction to all toxic substances (including alcohol and cannabis)
except tobacco.
- Current or past use of all toxic consumption (excluding alcohol, tobacco and
cannabis).
- Long-term Anticholinergic treatment.
- Related to the first degree diagnosed with a psychotic disorder